Photo Release: The Department of Disease Control (DDC), the Ministry of Public Health,

Food and Healthcare Press Releases Friday December 1, 2017 15:46
Bangkok--1 Dec--4D Communications

SOFFELL Enesis Group and Dr. Prawit Wairungruangkul (4th person from left), Managing Director of CP Consumer Products Co., Ltd., together with the company's executives gave Soffell mosquito repellents, value at 1,728,000 baht in total, to the Department of Disease Control, Ministry of Public Health. The products would be delivered to mobile health units to be given out to people in areas prone to dengue fever and Zika fever, both of which have mosquitos as vectors. Dr. Panumat Yannawetsakul (4th person from right), Deputy Director of the Department of Disease Control, received the gifts on behalf of the department. This preventive healthcare activity is one of the social activities that Soffell has been continuously doing.


Latest Press Release

Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that...

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide...

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...

Ozempic(R) Provided Greater Weight Reductions for Adults With a Baseline BMI ?25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Ozempic(R) (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults...

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated...

Related Topics